Walter A - Search Results

1

Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.

Gillen J, Gunderson C, Greenwade M, Rowland M, Ruskin R, Ding K, Crim A, Walter A, White E, Moore K. Gillen J, et al. Among authors: walter a. Gynecol Oncol. 2017 Apr;145(1):32-36. doi: 10.1016/j.ygyno.2016.12.023. Epub 2017 Jan 10. Gynecol Oncol. 2017. PMID: 28087143

2

Central nervous system metastasis in gynecologic cancer: symptom management, prognosis and palliative management strategies.

Walter AC, Gunderson CC, Vesely SK, Algan O, Sughrue M, Slaughter KN, Moore KN. Walter AC, et al. Gynecol Oncol. 2015 Mar;136(3):472-7. doi: 10.1016/j.ygyno.2014.12.020. Gynecol Oncol. 2015. PMID: 25752572

3

Society of Gynecologic Oncology 2016 Annual Meeting: Highlights and context.

Moore K, Stone R, Walter A. Moore K, et al. Among authors: walter a. Gynecol Oncol. 2016 Jun;141(3):416-420. doi: 10.1016/j.ygyno.2016.04.542. Gynecol Oncol. 2016. PMID: 27138457 No abstract available.

4

Post-intensive care unit syndrome in gynecologic oncology patients.

Gunderson CC, Walter AC, Ruskin R, Ding K, Moore KN. Gunderson CC, et al. Support Care Cancer. 2016 Nov;24(11):4627-32. doi: 10.1007/s00520-016-3305-0. Epub 2016 Jun 15. Support Care Cancer. 2016. PMID: 27306212

5

Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.

Crim A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, Gillen J, Ding K, Moore K, Gunderson C. Crim A, et al. Among authors: walter a. Gynecol Oncol. 2017 Aug;146(2):268-272. doi: 10.1016/j.ygyno.2017.05.032. Epub 2017 Jun 2. Gynecol Oncol. 2017. PMID: 28583323

6

Endometriosis-associated colorectal carcinosarcoma: A case report and review of the literature.

Tsolakian IG, Crim A, Lynn A, Zoorob D, Klein P, Walter A. Tsolakian IG, et al. Among authors: walter a. Gynecol Oncol Rep. 2021 Jan 12;35:100696. doi: 10.1016/j.gore.2021.100696. eCollection 2021 Feb. Gynecol Oncol Rep. 2021. PMID: 33537388 Free PMC article.

7

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.

Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: walter a. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.

8

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.

Walter A, Rocconi RP, Monk BJ, Herzog TJ, Manning L, Bognar E, Wallraven G, Aaron P, Horvath S, Tang M, Stanbery L, Coleman RL, Nemunaitis J. Walter A, et al. Gynecol Oncol. 2021 Dec;163(3):459-464. doi: 10.1016/j.ygyno.2021.10.004. Epub 2021 Oct 23. Gynecol Oncol. 2021. PMID: 34702567 Free article.

9

Total colectomy in primary ovarian cytoreduction.

Walter AC, Manahan KJ, Geisler JP. Walter AC, et al. Eur J Gynaecol Oncol. 2011;32(5):487-90. Eur J Gynaecol Oncol. 2011. PMID: 22053658

10

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.

Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Oh J, et al. Among authors: walter a. Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov. Gynecol Oncol Rep. 2020. PMID: 33364285 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,181 results

Search Page

Filters